All studies
Endocrinology · Claims + EHR · Japan

Wakabayashi 2023

Diabetes

ITTSuperiorityAcademia, Industry2/5 disclosures
Comparisons
3
In the analysis
3
all comparisons pooled
Target trials
3
Emulations reported
3
2 treatments

Comparisons

3 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Change in HbA1c, %
vs COMPASS·MD·Efficacy
-0.28-0.52–-0.04
-0.01-0.25–0.23
overlap1.56 SE apart
Change in HbA1c, %
vs Onishi et al.·MD·Efficacy
-0.28-0.46–-0.10
0.46-0.01–0.94
no overlap2.86 SE apart
Percentage changes in HbA1c levels (%)
vs PRIME-V·MD·Efficacy
4.030.79–7.27
-6.21-11.0–-1.40
no overlap-3.46 SE apart

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
1:1 PS matching
Analysis method
T-distribution (T-test)
Missing data
NR
Covariates adjusted
5
DAG
No
QBA
No

Data and sample

Data type
Claims + EHR
Data sources
1
Geography
Japan
Eligible sample
96
Treated
48
Control
48
Emulations
3
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
COI institutions
Clinical Study Support Inc.
Funding
Declared: Research institute, private
Funders
Juntendo University, Shin Nippon Biomedical Laboratories, Ltd

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2023_Wakabayashi_Diabetes
DOI
https://doi.org/10.1007/s40801-023-00353-7
Affiliations
Clinical Study Support, Inc., Nagoya, Japan, Real-World Evidence and Data Assessment (READS), Graduate School of Medicine, Juntendo University, Department of Radiology, School of Medicine, Juntendo University
Sector
Academia, Industry
Target trials (study level)
PRIME-V
Registration
UMIN000015170